The 4th Improving Immunohistochemistry Discussion Forum

London
Friday, 11 October 2013

This is a Euroscicon Small Conference,  an outline of the day can be found at 
www.euroscicon.com/EurosciconMeetingStructure.pdf

The 4th Improving Immunohistochemistry Discussion Forum
Friday, 11 October 2013 09:00 - 17:00

Cineworld: The O2
Peninsula Square
London
SE10 0DX
United Kingdom

Map and Directions

This event will be an ideal place to network, establishing lines of communication for the future if you ever need help with setting up  and improving IHC. This is a specialist meeting with many experts in the field, together in one room, giving you unrivalled access, all in one place. This event  has CPD accreditation.


Meeting chair:
Dr Will Howat, Cancer Research UK, Cambridge.


Who Should Attend:

Biotech and Pharma Industry: CEOs, Chief Scientists, Group Heads, Senior and Junior Scientists, Research Managers

Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students

Even experienced people who are interested in keeping up with the technique should be at this unique event as well as those learning from the beginning.


The deadline for abstract submissions for oral and poster presentation has now passed.


Talk times include 5 – 10 minutes for questions


9:00 – 9:45            Registration


9:45 – 10:00          Introduction by the Chair:  Dr Will Howat, Cancer Research UK, Cambridge.

10:00 – 10:30        What's new and what's coming in diagnostic molecular pathology?

Professor Bharat Jasani, Cardiff University School of Medicine, Institute of Cancer & Genetics, UK
Molecular Pathology has become established as a diagnostic discipline with the advent of molecular methods (FISH, PCR, DNA sequencing) capable of detecting cancer specific gene alterations (mutations, chromosomal translocations or gene amplifications) in formalin-fixed paraffin-embedded tissue sections. What's new is application of these methods to detection of a wide variety of cancers, sentinel lymph node metastases, and cancer subtype specific gene transcripts predictive of chemotherapy response or resistance. What's coming is genome wide sequencing capable of detecting inheritable SNPs and acquired gene alterations affecting cell signaling pathways and networks, allowing novel tumour specific diagnostics and treatment and monitoring strategies.

10:30 – 11:00         Is the fixative just a fixation?

Dr Francesca Chianini, Veterinary Research pathologist, Moredun Research Institute, Scotland, UK
It is well-known that for a successful outcome of immunohistochemical analysis tissues and cells need to retain as much as possible theiroriginal morphology and the antigenic sites of interest have to be accessible. This is why fixation plays a key role inimmunohistochemistry and depending on target antigens to be labelled the most adequate fixative should be carefully chosen. Formalinfixed tissues are well suited for a variety of studies, but in same cases, as when investigating cells of the immune system, using azinc-salt solution could play a pivotal role for good results.


11:00 – 11:30         Speakers’ photo then mid-morning break and poster exhibition and trade show


11:30 – 12:00         A practical approach to multiple antigen detection using immunohistochemistry

Dr Henny Martineau,  Lecturer in Veterinary Pathology  Royal Veterinary College, UK
The ability to label multiple antigens within a single section of fixed tissue using immunohistochemistry, is a powerful tool for bothdiagnostic and research pathologists. However, the potentially complicated and laborious methodology can be off putting. This talk willillustrate the basic principles of multiple antigen labelling, and its application in a research setting.

12:00  – 12:30          Phenotyping TILs In Situ: Automated enumeration of FOXP3+ and CD69+ T cells in follicular lymphoma

Dr Richard Byers, Senior Lecturer in Pathology, University of Manchester / Consultant Histopathologist, Manchester Royal Infirmary, UK
Increased regulatory T cells (Tregs) are associated with poor prognosis in cancer and understanding of the phenotype and spatialdistribution of Tregs in situ would be advantageous. A tissue microarray comprising 66 follicular lymphoma samples was used in tripleximmunohistochemistry for FOXP3, CD3 and CD69. Multispectral imaging was used to determine the numbers of CD3+ve andFOXP3/CD3+ and CD69/CD3+ positive T-cells. Kaplan-Meier analysis was used to determine prognostic significance of CD3+,FOXP3/CD3+ and CD69/CD3+ positive T-cells. Higher numbers of CD3 single positive cells, double positive FOXP3+CD3+ cells anddouble positive CD69+ CD3+ cells were significantly associated with a favourable outcome.

12:30  – 13:00   No Antibody? No Problem.   

Dr Kai Wilkens, PhD MBA, Advanced Cell Diagnostics, Inc
Because over 70% of protein-coding genes have no reliable antibody for immunohistochemistry (IHC), research can come to a screeching halt while you wait for new antibodies to be developed. Whether your target is a novel gene with no commercial antibody available, a secreted protein with poor-quality antibodies for IHC, or a non-coding RNA our universal assay workflows and rapid probe design for any gene, eliminates the hassles of antibody screening, saving you precious time and effort, while delivering publication quality data today.

13:00  – 14:00        Lunch, poster exhibition and trade show


14:00 – 15:00         Question and Answer Session


15:00 – 15:30         Variable expression of estrogen receptor in basal-like breast carcinomas

Mrs Jennifer R. Won, PhD Candidate, University of British Columbia, Canada
Basal-like breast cancer is a particularly aggressive subtype. Since gene expression profiling methodologies are not widely accessible, surrogate immunohistochemical definitions for its identification typically rely on ER, PR and HER2 negativity. In an international survey of clinical laboratories, 46 of 48 participants demonstrated ER-positivity rates from 0 to 13.3% in basal-like carcinoma cases, while 2 laboratories possessed an abnormally high ER-positivity rate of 60%. Focusing on the basal-like subtype revealed considerable variability in ER staining. False-positive cases due to loss of staining specificity may be caused by suboptimal protocols that employ specific primary antibody clones and detection systems.


15:30 – 16:00          Afternoon Tea,  last poster session and trade show

   

16:00 – 16:30          Breast Estrogen and Progesterone Receptor Immunohistochemistry: Are we any closer to

standardisation?

Dr Merdol Ibrahim, Manager UK NQAS ICC & ISHb, University College London (UCL), UK
Breast biomarker immunohistochemistry, including estrogen (ER), progesterone (PR) and HER2 markers are routinely used in theclinical setting, for the correct classification and subsequent selection of patients for correct treatment regime. However, there is nostandardised kit or method employed for either ER or PR immunohistochemistry, with variability in staining (mainly false- positive)driven by various factors including choice and dilution of antibody, pH of antigen retrieval and more sensitive detection systems. Thereis still therefore still a need to improve breast biomarker immunocytochemistry, with laboratories encouraged to validate theirmethodologies and include adequate control material to gauge the sensitivity and specificity of their methods.

16:30 – 17:00         Using immunohistochemistry to differentiate M1 and M2 macrophages in COPD lung tissue

Dr Sarah Bolton, Scientific Consultant,  Sarah Bolton Ltd, The Research Network, UK
Tissue macrophages can be classified as either M1 (classically-activated) macrophages, which are pro-inflammatory with reducedcapacity for phagocytosis or M2 (alternatively-activated) macrophages which are more phagocytic with a pro-repair capacity. Thephenotype of macrophages in cancer tissue has been shown to correllate with disease prognosis. Macrophages from COPD patientsare known to have reduced capability for phagocytosis, which could contribute to bacterial infections as well as exacerbate existinginflammation. We sought to investigate, using immunohistochemistry, the macrophage phenotypes in COPD lung and whether onephenotype was associated with a particular microenvironment.

17:00                    Chairman’s Summing Up and Close of Meeting


Keywords:   Tissue Microarrays, immunohistochemistry, fixation, imaging, quantitation,glycol methacrylate resin, immunohistochemistry, fixation, Immunohistochemistry, tissue micro array, formalin fixed paraffin embedded material, high through put, quantifying biomarkers, clinical tissues, automated-analysis, In situ hybridization, IHC validation, RNAscope, digital pathology, gene expression, immunoprofiling, immune, tumour, new methods diagnostic molecular pathology, estrogen receptor, basal-like breast cancer, external quality assurance, molecular subtype, fixation, post-fixation, brain, immune system, cells, Immunohistochemistry, multiple antigen detection, breast biomarkers, estrogen receptor, progesterone receptor, immunohistochemistry,  quality control, COPD, Macrophages, Immunohistochemistry, Human, Inflammation


Registration Website: http://www.regonline.co.uk/IHC2013


 

Contact Details

Payment Instructions

  • For enquiries regarding payment email:  accounts@euroscicon.com

    You can pay by - Credit card, Cheque, Purchase Order or Bank transfer.
    Payment must be received prior to the meeting

    Credit card
    You can pay during your online registration using your credit card. The information taken will be by secure server and we use Worldpay and PayPal for our credit card transactions. We always prefer debit cards for transactions, but can also take credit cards and American Express. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered

    Cheque Payment
    Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process).  After registration you will be emailed details of where to send your cheque.

    Purchase Order

    Please input your Purchase Order number in the box provided once you have selected your mode of payment and an invoice will be sent to you accordingly

    Bank transfer
    Clients organizing bank transfers from non-UK banks will need to pay an additional administration fee of £15.00. Please ensure that you add this fee onto your payment to ensure successful registration.  
    After registration you will be emailed details of where transfer your money.

        Linked in   
An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Trading Address:  Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK.  Registered Office: 47 High Street, Barnet, Herts, EN5 5UW, UK 


© 2016
Quick, easy and affordable online event registration and event management software for all event sizes.